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IN T R O D U C T IO N  
Screening of more than 5000 German breast and ovarian cancer families by PCR based techniques revealed that 
in high risk groups, mutation frequencies in the two known BRCA genes reach between 35-50% (Meindl, 2002). In 
contrast, mutations in other predisposing genes like CHEK2 (Dufault et al., 2004), ATM (Dork et al., 2001) and 
RAD51C (Meindl et al., 2010) were detected with low prevalence. As a significant proportion of our families 
lacking mutations in the BRCA1, BRCA2, RAD51C, CHEK2 or ATM genes, respectively, suggests a strong genetic 
background, we decided to screen for mutations in PALB2, an additional breast cancer predisposing gene described 
recently.   
PALB2 encodes for a protein functioning as Partner and Localizer of BRCA2 (PALB2; MIM# 610355). It has 
been recently associated with recessive mutations in Fanconi anemia (MIM# 227650) (Xia et al., 2007; Reid et al., 
2007) and heterozygous mutations in familial breast cancer (Rahman et al., 2007).  Moreover, a recurrent founder 
mutation has been reported for the Finnish population (Erkko et al., 2007). Interestingly, truncating PALB2 
mutations have also been found in familial pancreatic cancer cases (Jones et al., 2009). 
The relative contribution of PALB2 mutations to familial breast cancer cases for most populations, including the 
German one, is still largely unknown. Besides the Finnish founder mutation only one rare founder mutation has 
been described in a small study with French-Canadian breast cancer families (Foulkes et al., 2007). Complete 
analysis of the PALB2 gene in 95 Spanish breast cancer families revealed only one novel mutation, which was not 
present in another 725 high risk breast cancer cases (Garcia et al., 2009). Moreover, sequencing of the entire 
PALB2 gene in 360 Chinese women with early-onset breast cancer revealed only two novel truncating mutations 
present in three out of 360 families, which were further validated in a larger set of BRCA1/2 negative Chinese 
samples (Cao et al., 2009). Finally, two novel aberrations were identified very recently in Italian families (Papi et 
al., 2009; Balia et al., 2010).  Here we present the complete screening for mutations in the PALB2 gene in 818 
familial cases of breast cancer from Germany.  
 
 
M A T E R IA L S  A N D  M E T H O D S  
P a tie n ts  an d  F am ilie s  
Index patients from 818 unrelated breast cancer families were recruited through a clinicogenetic counselling 
setting at the Familial Breast and Ovarian Cancer Centers in Cologne, Düsseldorf, Heidelberg, Kiel, Munich and 
Ulm. They had been categorized in different risk groups: Group A: three or more affected females with breast 
cancer, at least two of them diagnosed before the age of 50 ys (n = 330); Group B: three or more affected females 
independent of age (including families with one breast cancer case <50ys, n = 229); Group C: two cases of breast 
cancer diagnosed before the age of 50 ys (n = 68); Group E: at least one case of breast and one ovarian cancer, 
respectively (n = 143). All affected index patients had been screened for small nucleotide alterations in BRCA1 and 
BRCA2 by the PCR-based mutation detection techniques dHPLC and/or direct DNA-sequencing (Meindl, 2002) 
and tested negative for pathogenic mutations. DNAs from 450 control samples from healthy women aged older 
than 50 years were collected in Kiel (100), Düsseldorf (150) and Munich (200).  
D irec t seq u en c in g  
PCR and sequencing pimers are listed in Supp. Table S1. DNAs were amplified using AmpliTaq Gold or 
Platinum Taq DNA polymerase (Invitrogen) or the Expand High Fidelity PCR system (Roche). Sequencing was 
carried out after PCR amplification of all 13 exons of the PALB2 gene by using the same primers in the chain 
terminating reaction. Sequence reactions were electrophoresed on an ABI 3100 automated DNA sequencer 
(Applied Biosystems, Darmstadt, Germany). Sequences were analysed by using Sequence Pilot software (JSI-
Medisys, Kippenheim, Germany) and by visual inspections of chromatograms. Reference sequence was obtained 
from NM_024675.3 using the first nucleotide of the ATG translation start as +1.  
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D en atu rin g  h ig h  p ressu re  liq u id  ch ro m ato g rap h y  (d H P L C ) an d  h ig h  reso lu tio n  m e ltin g  an a lys is  (H R M ) 
The detection of sequence variants in exons 1, 2, 6, and 8-13 was carried out by dHPLC analysis as described 
elsewhere (Xiao and Oefner, 2001). In brief, the mutation analysis was done on a Wave DNA fragment analysis 
system (Transgenomic, Omaha, NE) under partially denaturing conditions. PCR products were heated up to 95°C 
and slowly cooled down to generate heteroduplex molecules in the case of heterozygous DNA samples. The 
optimal system performance was checked by standard samples (Transgenomic) and positive controls generated by 
in vitro mutagenesis (see below).  
Exons 3, 4, 5 and 7 were screened by HRM analysis on a Lightcycler 480 instrument (Roche, Penzberg, 
Germany) using the Gene scanning software module of the system and a sensitivity setting of 0.30. Melting 
differences were visualized by Difference plots. 
In  v itro  m u tag en es is   
To supply positive controls for a dHPLC/HRM screening, mutations were generated by in vitro mutagenesis 
(see asterisks in Fig. 1). We used the Quick changeR II Site-Directed Mutagenese kit (Stratagene, Heidelberg, 
Germany).  
P red ic tio n  o f p a th o g en ic ity  o f m issen se  va rian ts  
Potential consequences of missense mutations were obtained by using the prediction softwares SIFT 
(http://sift.jcvi.org/), PolyPhen (http://genetics.bwh.harvard.edu/pph), and Mutation Taster 
(http://www.mutationtaster.org/).  
 
R E S U L T S  
M u tatio n  a n a lys is  o f th e  P A L B 2  g en e  in  fam ilia l b reas t can cer cases  
In order to determine PALB2 mutation frequencies already identified in other populations (Fig. 1a) and/or to 
detect novel PALB2 sequence variations in the German population, we decided to sequence in a first step all 13 
coding exons of the entire PALB2 gene in 108 familial breast cancer cases, which were enriched for high risk 
families from group A and E. Two novel truncating mutations in exon 4 (c.1240C>T, p.R414X) and exon 5 
(c.2145_2146delTA, p.D715EfsX2) were found (Fig. 1b and Table 1), whereas none of the published clearly 
pathogenic PALB2 mutations were detected. In addition, we identified a novel, probably disease causing missense 
variant in exon 13 (c.3428T>C; p.L1143P, see below). Additional 710 families were screened for PALB2 
mutations using the dHPLC and HRM high throughput techniques (see Fig. 1c). To establish the assay conditions, 
at least one positive mutational control was used. As for some of the exons mutated genomic DNAs were not 
available, we generated additional mutated templates by in vitro mutagenesis for an effective and reliable 
screening with respect to all melting domains of the amplicons (see Fig. 1, mutations with asterisks).  
None of the known published truncating mutations (Erkko et al., 2007; Cao et al., 2009; Garcia et al., 2009; 
Rahman et al., 2007; Foulkes et al., 2007; Sluiter et al., 2009; Adank et al., 2010; Dansonka-Mieszkowska et al., 
2010; Balia et al., 2010), except one single nonsense mutation in exon 5 (c.2257C>T; p.R753X) (Papi et al., 2009), 
as well as none of our two novel mutations and the one putative pathogenic missense variation identified by direct 
sequencing, could be found in the 710 additional familial cases. However, we could identify one novel splice 
mutation in exon 1 (c.48+1G>C), one novel frameshift mutation in exon 3 (c.172_175delTTGT, p.Q60RfsX7), and 
two further novel nonsense mutations in exon 4 (c.503C>A), and exon 9 (c.2962C>T) causing direct introduction 
of premature stop codons at the positions p.S168X and p.Q988X, respectively. The family history and 
histopathology of the tumor tissues of our index patients is indicated in Table 1.  
Moreover, we identified by the dHPLC and HRM method additional 11 novel missense variants (Supp. Table 
S2). The application of three different prediction programs and conservation profiles indicated that only one of 
them might be disease associated (c.3128G>C; p.G1043A).  
Several observations support the classification of the missense mutations L1143P and G1043A as pathogenic: 
a) not present in 450 healthy controls, b) highly evolutionary conserved, and c) all the three prediction algorithms 
PolyPhen, SIFT and Mutation Taster predicted a damaging effect on the protein. Nevertheless, they still have to be 
considered as unclassifed variants and functional analyses are warranted. This also applies for the missense 
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mutations G998E and L939W, which are both present in patients and controls, however, overrepresentation of 
both changes in patients cannot be ruled out currently. Finally, one complex change in the 5`UTR,  
c.-214_236delins10, was found both once in patients and controls, but RNA analysis is required for a final 
characterization. This might also be indicated for two intronic aberrations (c.49-15t>c; c.109-12t>a), which were 
found each once in patients, but not in controls.   
 
P atien ts ’ an d  fam ily  ch arac te ris tics  o f id en tified  m u ta tio n  ca rrie rs  
In total, we identified seven truncating mutations and two putative pathogenic missense mutations in the 818 
familial cases (Table 1). As an extensive segregation analysis was available only in two families (e. g. Fig. 2), 
calculation of penetrance for our families revealed to be difficult. However, based on the obtained and partially 
documented family data, it can be considered as high, supporting the observation of higher ORs of clearly 
pathogenic PALB2 mutations within a familial context (Byrnes et al., 2008; Southey et al., 60th Annual meeting of 
the ASHG, Washington DC, 2010). The appearance of a PALB2 mutation might not be associated with breast 
cancer only, but also with colon/ovarian cancer. Concerning histology, PALB2 mutations can cause either hormone 
receptor positive, but equally hormone receptor negative breast cancer. As previously observed (Tischkowitz and 
Xia, 2010), estrogen/progesterone receptor negative carcinomas appear therefore to be slightly overrepresented in 








































































































































































Figure 1. Truncating mutations in the PALB2 gene. a) Localization of the previously reported deleterious mutations in the 
PALB2 gene identified in breast cancer families; published mutations indicated by an asterisk were additionally prepared by in 
vitro mutagenesis for the purpose of using them as positive controls for the dHPLC screening (see 1c). b) Depiction of novel 
mutations found by direct sequencing in 108 familial cases tested negative for BRCA1/2 mutations; c) Mutation sites in the 
PALB2 gene found in 710 familial cases analysed by dHPLC and HRM analysis. 
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T ab le  1 . T ru n catin g  an d  p u ta tive  d e le te rio u s  m issen se  m u ta tio n s  in  th e  P A L B 2  g en e  in  818  fam ilia l b reast can cer 
cases  
 




Figure 2. Segregation of the nonsense mutation p.Q988X in a breast cancer family.  a) Pedigree of the family. b) 
Corresponding sequence alteration c.2962C>T (p.Q988X) detected in exon 9 of the PALB2 gene. Additional pedigrees of the 





Family history Tumor histology of index 
patient 
1 c.48+1G>C Splice defect 3 x  BC with late onset > 60ys HR+, HER2neu-  
3 c.172_175delTTGT p.Q60RfsX7 1 BC, 1 OC + colon cancer Invasive ductal carcinoma at 
age 46, HR+/HER2neu- 
4 c.503C>A p.S168X 2 x BC Ductal carcinoma in situ at 
39ys, HR-  
4 c.1240C>T p.R414X 4 x BC (one bilateral case with 
subsequent onset of OC or 
uterine cancer),  
Invasive intraductal BC at 43ys, 
HR- 
5 c.2145_2146delTA p.D715EfsX2 3 x BC, 1 putative OC Invasive ductal carcinoma at 
44ys, HR+ 
5 c.2257C>T p.R753X 3 x BC BC at age 33ys, HR- 
9 c.2962C>T p.Q988X 4 x BC  (one bilateral case), see 
also Fig. 2 
Ductal carcinoma in situ of one 
sister, moderately HR+; grade 3 
tumor of other sister HR- 
11 c.3128G>C p.G1043A 2 x BC  ( two affected sisters, 
but only one mutation carrier) 
unknown 
13 c.3428T>C p.L1143P 2 x BC  (one bilateral case) Bilateral BC at age 40 and 45 of 
unknown histology 
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D IS C U S S IO N  
The PALB2 gene product is one of approximately ten proteins which directly complex with or bind to BRCA1 
or BRCA2. The PALB2 protein interacts at the site of four WD40 domains with the very N-terminus of BRCA2 
and at the very N-terminal site with a heptad coiled coil stretch in BRCA1, thus stabilizing its nuclear functions in 
DNA repair (Xia et al., 2006; Sy et al., 2009b; Zhang et al., 2009; Zhang et al., 2009). Patients lacking a functional 
PALB2 protein on the basis of inactivating mutations either develop Fanconi anemia (FANCN) or familial breast 
cancer. Moreover, truncating mutations have also been reported for familial pancreatic cancer (Jones et al., 2009). 
More than 20 distinct clearly pathogenic mutations have been reported in the literature (most of them summarized 
in ref. Jones et al., 2009; quite novel ones in ref. Dansonka-Mieszkowska et al., 2010; Papi et al., 2009; Balia et al., 
2010) or in international databases, e.g. HGMD, so far. However, only 16 of them have been identified in breast 
cancer families (see Fig. 1a). Based on these findings we were prompted to study 818 unrelated German familial 
breast cancer patients tested negative for BRCA1/2, together with 450 unaffected controls. In addition to the 
recently and quite actually published data (Papi et al., 2009; Dansonka-Mieszkowska et al., 2010; Balia et al., 
2010), we could add six novel truncating mutations and two novel putative disease contributing missense variants.  
P o p u la tio n  an d  e th n ic ity  sp ec ific  m u ta tio n  p ro files  fo r th e  P A L B 2  g e n e  
Our data convincingly support the evidence of population-specific mutational profiles for the PALB2 gene. 
Only one out of the truncating mutations described here has been found before in other breast cancer families from 
different geographic or ethnic origin, nor were we able to find any of the published mutations in our population. 
Likewise, in addition, we could exclude the occurrence of the recurrent Finnish founder mutation (Erkko et al., 
2007), the four distinct truncating PALB2 mutations found in nine British breast cancer families of mixed ethnical 
background (Rahman et al., 2007), and the recurrent mutation (c.2323C>T) in the French-Canadian population 
(Foulkes et al., 2007), in our 818 familial cases. The nonsense mutation c.2257C>T, found in a breast cancer 
family from Italy, had been published after finding this mutation in our cohort.  
So far, the identified mutations in the PALB2 gene are scattered among the entire gene and seem to be of very 
low frequency and distinct for different populations. The lack of recurrent founder mutations for most of the 
Caucasian populations or other ethnicities seems therefore to require initial comprehensive mutation screenings for 
the different populations or ethnicities. However, large genomic rearrangements in the PALB2 gene do not appear 
to contribute to the hereditary breast cancer susceptibility as reported by two independent publications (Ameziane 
et al., 2009; Pylkas et al., 2008).   
U n c lass ified  varian ts  in  th e  P A L B 2  p ro te in   
The prevalence of truncating mutations in the PALB2 gene is in the range of about 1.0% (Fig. 1 and ref. 
Turnbull and Rahman, 2008). The importance of PALB2 as a predisposing gene for familial breast cancer might on 
the other hand be increased by the detection and characterization of additional protein affecting missense 
mutations. For example, it has been reported that the PALB2 protein directly interacts with the very 5´end of the 
BRCA2 protein (Xia et al., 2006; Sy et al., 2009b; Zhang et al., 2009), and recently it has been shown that the 
aminoterminal part of the PALB2 protein is required for binding a coiled-coiled domain of BRCA1 (Sy et al., 
2009a; Zhang et al., 2009). Obviously, amino acid substitutions in these binding domains might be pathogenic. In 
agreement with these observations, we could find two missense mutations in this study, which are most likely 
pathogenic (p.T1030I and p.L1143P) and located in a domain of the PALB2 protein, which is interacting with 
BRCA2 (Sy et al., 2009a). Functional studies are underway to systematically investigate these putative pathogenic 
missense mutations by complementation assays (Takata et al., 2001). On the other hand, we identified four novel 
aberrations in the 5´UTR and intronic part of the gene, which might cause either aberrant expression or splicing of 
the gene. RNA analysis experiments are underway. Two missense mutations (L939W, G998E) were found in 
patients and controls. Both seemed to be slightly overrepresented in patients, both are highly conserved and both 
were predicted to be deleterious by three algorithms. Their putative character as low risk variants should be 
clarified by the application of an extensive case-control study.  
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Im p act o n  th e rap y  an d  g en e tic  co u n se lin g  
As BRCA1- and BRCA2–deficient cells have been found to be highly sensitive to poly(ADP-ribose) polymer-
rase (PARP) inhibition, it has been assumed that this would be true as well for tumors lacking PALB2. Indeed, it 
could be shown recently that PARP inhibitor AZD2281 was cytotoxic to PALB2-mutant lymphoblasts (Buisson et 
al., 2010). Hence, regarding the favorable treatment options by PARP inhibitors observed in familial BRCA1/2-
associated breast cancer cases (Fong et al., 2009), the presence of PALB2 mutations should be of clinical 
relevance for providing tailored therapy regimens to the respective patients. 
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Supp. Figure S1.  Pedigrees of the breast cancer families harbouring PALB2 mutations. 
 
P A L B 2  M u tatio n s  in  F am ilia l B reas t C an cer C ases   E 2186  
 





Exon Forward Primer Reverse Primer 
1 5' - ACTGGGACTCATCGACAGC - 3' 5' - TGGTCAGATGATACTGCTGC - 3' 
2 5' - TTATGGACCAGTGCTACTCC - 3' 5' - AGCTCTTTGGGCACGCTAG - 3' 
3 5' - GCCTTCAGGTAAGTGAATCG - 3' 5' - TCTTCACACTGTGGGAAAAAG - 3' 
4a 5' - CATCTGCCTGAATGAAATGTC - 3' 5' - GGGGAAAATGTTCTTGGGTG - 3' 
4b 5' - CCCAGGAGGATTACCTATAC - 3' 5' - GGCAGTTGGTGGAATTAATAC - 3' 
4c 5' - AATCTGAACTTCCAGATTCTC - 3'  5' - TAGAACTTGTGGGCAGTTGG - 3' 
4d 5' - GACTGTCTCTACAGATAACC - 3' 5' - CTTTCCTCTGGCAATTGGAC - 3' 
4e 5' - GGCCTTCTGTTTCCTGCAG - 3' 5' - CTTGGACCTGTTAACAATCG - 3' 
4f 5' - TGACTTGTCTAGGAAGGCAG - 3' 5' - AGGAAGTGCCAGGCAAATAG - 3' 
5a 5' - GGAGATCCTATTCTCTTTGTC - 3' 5' - TTTGACTCAAAGGGCTCCAC - 3' 
5b 5' - AAGACTTTGGACCTCTTAAGC - 3' 5' - TTTCATAGGAGCCTTGAGGG - 3' 
5c 5' - TCCTTTAAATACGGTTGCGC - 3' 5' - TGCGCAAGCAAGTCATGCTG - 3' 
6 5' - TGCATTTGGAGCTTTGCTGC - 3' 5' - AGAACAAGAAGCTATATGACTG - 3' 
7 5' - TTCTTTTCACCTGCATAAGAC - 3' 5' - CCAATTTTGGTAAGCTGCCC - 3' 
8 5' - ATCCTTGTACAGTGAGAATAC - 3' 5' - TTTCAAGACTCAAGCCTAGG - 3' 
9 5' - AGGTTACTCCTCACATCACC - 3' 5' - AAACGAGATCCTAGTTACCC - 3' 
10 5' - GCAGTTCAACAATGCGGAGAAG - 3' 5' - GAGGTATATCCTCATACTACAG - 3' 
11 5' - CCCACAGTTCTACTTTTACC - 3' 5' - GGGGAAGGTTTGTTCATTAC - 3' 
12 5' - TTTGGTTTTTGTCTCTGCCAG - 3' 5' - TCAGAATGTCCCACCCATAG - 3' 
13 5' - TTGTTTTTTGGATATGTAATCTG - 3' 5' - AAGTGTCATTCAGATATTCTCC - 3' 
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Exon Nucleotide change1 Protein 
change 
in dbSNP conservation PolyPhen: SIFT: Mutation Taster: 
fam 1 1 c.-214_236delins10  no - - - - 
fam 4 1 c.-158G>C  no high - - - 
fam 12 1 c.-47G>A  rs8053188 medium - - - 
fam 1 2 c.49-15T>C  no high - - - 
fam 1 3 c.109-12T>A   no high - - - 
fam 1 3 c.136C>T H46Y no low probably damaging affect Protein Function polymorphism 
fam 1 4 c.656A>G D219G rs45594034 no benign tolerated polymorphism 
fam 1 4 c.939C>T  G313G no silent mutation  - tolerated polymorphism 
fam 1 4 c.1001A>G Y334C no high benign tolerated polymorphism 
fam 15 4 c.1010T>C L337S rs45494092 no possibly damaging tolerated polymorphism 
fam 3 4 c.1194G>A V398V rs61755173 silent mutation  - tolerated polymorphism 
fam 1 4 c.1273G>A V425M no high benign tolerated polymorphism 
fam 1 4 c.1419A>C P473P rs62625275 silent mutation  - tolerated polymorphism 
fam 1 4 c.1471G>A A491T no not at all benign tolerated polymorphism 
fam 1 4 c.1563C>T  T521T no silent mutation  - tolerated polymorphism 
fam 2 4 c.1572A>G S524S rs45472400 silent mutation  - tolerated polymorphism 
fam 127 4 c.1676A>G Q559R rs152451 no benign tolerated polymorphism 
fam 1 5 c.1935G>A E645E no silent mutation - tolerated polymorphism 
fam 48 5 c.2014G>C E672Q rs45532440 no benign tolerated polymorphism 
fam 1 5 c.2135C>T A712V no low benign tolerated polymorphism 
fam 1 5 c.2182T>C F728L no very high probably damaging tolerated disease causing 
fam 9 7 c.2590C>T P864S rs45468339 high probably damaging tolerated polymorphism 
fam 1 8 c.2750T>C V917A no high benign affect Protein Function polymorphism 
fam 11 8 c.2794G>A V932M rs45624036 very high benign tolerated polymorphism 
fam 6 8 c.2816T>G L939W rs45478192 very high probably damaging affect Protein Function disease causing 
fam 31 9 c.2993G>A G998E rs45551636 very high probably damaging affect Protein Function disease causing 
fam 1 10 c.3057C>T V1019V no silent mutation  - tolerated polymorphism 
fam 1 10 c.3073G>A A1025T no high benign affect Protein Function disease causing 
fam 1 11 c.3128G>C G1043A no very high possibly damaging affect Protein Function disease causing 
fam 1 12 c.3223A>G S1075G no high possibly damaging tolerated polymorphism 
fam 47 12 c.3300T>G T1100T rs45516100 silent mutation  - tolerated polymorphism 
fam 1 12 c.3314T>C V1105A no very high possibly damaging tolerated polymorphism 
fam 1 12 c.3342G>C Q1114H no medium benign tolerated polymorphism 
fam 1 13 c.3428T>C L1143P no high probably damaging affect Protein Function disease causing 





Exon Nucleotide change Protein 
change 
in dbSNP conservation: PolyPhen: SIFT: Mutation Taster: 
con 1 1 c.-214_236delins10 - no - - - - 
con 2 1 c.-158G>C - no high - - - 
con 1 1 c.-109delG - no - - - - 
con 6 1 c.-47G>A - rs8053188 medium - - - 
con 15 4 c.1010T>C L337S rs45494092 no possibly damaging tolerated polymorphism 
con 1 4 c.1194G>A V398V rs61755173 silent mutation  - tolerated polymorphism 
con 1 4 c.1241G>A R414Q no very high possibly damaging tolerated polymorphism 
con 1 4 c.1544A>G K515R no high-very high benign tolerated polymorphism 
con 6 4 c.1572A>G S524S rs45472400 silent mutation  - tolerated polymorphism 
con 67 4 c.1676A>G Q559R rs152451 no benign tolerated polymorphism 
con 16 5 c.2014G>C E672Q rs45532440 no benign tolerated polymorphism 
con 4 7 c.2590C>T P864S rs45468339 high probably damaging tolerated polymorphism 
con 5 8 c.2794G>A V932M rs45624036 very high benign tolerated polymorphism 
con 2 8 c.2816T>G L939W rs45478192 very high probably damaging affect Protein Function disease causing 
con 1 9 c.2896 A-G I 966V no very high benign tolerated polymorphism 
con 12 9 c.2993G>A G998E rs45551636 very high probably damaging affect Protein Function disease causing 
con 1 12 c.3297G>A T1099T rs45565738 silent mutation - tolerated polymorphism 
con 17 12 c.3300T>G T1100T rs45516100 silent mutation  - tolerated polymorphism 
con 2 13 c.3495G>A S1165S rs45439097 silent mutation  - tolerated polymorphism 
con 2 13 c.3508C>T H1170Y no high probably damaging tolerated polymorphism 
 
       1  possibly protein damaging unclassified variants in bold,  nucleotide numbering is based on cDNA starting with the first nucleotide of the ATG translation initiation codon    
 
  
 
